NeuroDerm is focused on developing innovative drug-device combination solutions specifically for central nervous system disorders, with a strong emphasis on Parkinson's disease. Their flagship product, ND0612, is a proprietary formulation of the established medications levodopa and carbidopa, designed for continuous subcutaneous delivery. This advanced delivery system aims to address the challenges faced by Parkinson's patients, particularly those experiencing motor fluctuations, by providing a more consistent and effective treatment option. The integration of digital solutions further enhances the user experience, making the treatment more accessible and manageable for patients.

The company is committed to improving the quality of life for patients and their families through its patient-centric approach. By leveraging state-of-the-art technology, NeuroDerm aspires to redefine the standard of care in Parkinson's disease management. Their ongoing clinical trials, including the Phase 3 BouNDless trial, demonstrate their dedication to rigorous scientific evaluation and innovation in the healthcare landscape. Through these efforts, NeuroDerm aims to reduce the disease burden and foster a future where patients can regain control over their lives.

Israel

NeuroDerm is an agile and entrepreneurial R&D company, driving healthcare innovation and patient-centric solutions through Pharma & MedTech integration.

By developing next-generation drug-device combination solutions for central nervous system disorders, we aspire to make a meaningful difference in patients’ lives and drive future healthcare connectivity.

Our mission is to address the challenges of the future healthcare and wellbeing ecosystem. We are passionately driven to reduce disease burden and improve the quality of life of patients and their families through innovative drug-device combination therapies and technologies.

NeuroDerm

Company Details